Editorial: Preclinical macaque models of viral diseases DOI Creative Commons
Jeremy Smedley

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Nov. 9, 2023

EDITORIAL article Front. Immunol., 09 November 2023Sec. Viral Immunology Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1331774

Language: Английский

Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells DOI Creative Commons
Asier Sáez‐Cirión, Anne‐Claire Mamez, Véronique Avettand-Fènoël

et al.

Nature Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 2, 2024

Language: Английский

Citations

15
Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study DOI Creative Commons
María Salgado, Cristina Gálvez, Monique Nijhuis

et al.

The Lancet HIV, Journal Year: 2024, Volume and Issue: 11(6), P. e389 - e405

Published: May 28, 2024

Language: Английский

Citations

10
HIV Reservoirs and Treatment Strategies toward Curing HIV Infection DOI Open Access
Kouki Matsuda, Kenji Maeda

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(5), P. 2621 - 2621

Published: Feb. 23, 2024

Combination antiretroviral therapy (cART) has significantly improved the prognosis of individuals living with human immunodeficiency virus (HIV). Acquired syndrome transformed from a fatal disease to treatable chronic infection. Currently, effective and safe anti-HIV drugs are available. Although cART can reduce viral production in body patient below detection limit, it cannot eliminate HIV provirus integrated into host cell genome; hence, will be produced again after discontinuation. Therefore, research cure (or remission) for been widely conducted. In this review, we focus on drug development targeting cells latently infected assess progress including our current studies, particularly terms “Shock Kill”, “Block Lock” strategies.

Language: Английский

Citations

7
Deep Thought on the HIV Cured Cases: Where Have We Been and What Lies Ahead? DOI Creative Commons
Qing Xiao, Sanxiu He, Chaoyu Wang

et al.

Biomolecules, Journal Year: 2025, Volume and Issue: 15(3), P. 378 - 378

Published: March 5, 2025

Antiretroviral therapy (ART) can effectively suppress the replication of human immunodeficiency virus (HIV), but it cannot completely eradicate virus. The persistent existence HIV reservoir is a major obstacle in quest for cure. To date, there have been total seven cured cases worldwide. These patients all cleared while undergoing allogeneic stem cell transplantation (allo-HSCT) hematological malignancies. However, these cases, specific mechanism by which allo-HSCT leads to eradication remains unclear, so necessary conduct an in-depth analysis. Due difficulty obtaining donors and risks associated with transplantation, this treatment method not applicable patients. There still need explore new strategies. In recent years, emerging therapies such as neutralizing antibody immunotherapy, chimeric antigen receptor T (CAR-T) therapy, gene editing, antiviral targeting attracted wide attention due their ability inhibit replication. This article first elaborates on nature reservoir, then deeply explores modalities potential success factors finally discusses current novel methods, hoping provide comprehensive feasible strategies achieving cure HIV.

Language: Английский

Citations

0
Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure DOI Creative Commons

Amber Khan,

Paneerselvam Nandagopal,

Brian R. Lawson

et al.

Clinical Immunology, Journal Year: 2023, Volume and Issue: 255, P. 109741 - 109741

Published: Aug. 21, 2023

Language: Английский

Citations

7
Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection DOI
Gabriela M. Webb,

Cleiton Pessoa,

Allyson J. McCullen

et al.

Journal of Virology, Journal Year: 2024, Volume and Issue: 98(6)

Published: May 22, 2024

TIGIT is a negative immune checkpoint receptor associated with T cell exhaustion in cancer and HIV. upregulation virus-specific CD8

Language: Английский

Citations

2
Cytomegalovirus vaccine vector-induced effector memory CD4 + T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge DOI Creative Commons
Daniel Malouli,

Meenakshi Tiwary,

Roxanne M. Gilbride

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: July 19, 2024

Abstract An influenza vaccine approach that overcomes the problem of viral sequence diversity and provides long-lived heterosubtypic protection is urgently needed to protect against pandemic viruses. Here, determine if lung-resident effector memory T cells induced by cytomegalovirus (CMV)-vectored vaccines expressing conserved internal antigens could lethal challenge, we immunize Mauritian cynomolgus macaques (MCM) with CMV (CyCMV) H1N1 1918 M1, NP, PB1 (CyCMV/Flu), challenge heterologous, aerosolized avian H5N1 influenza. All six unvaccinated MCM died seven days post infection acute respiratory distress, while 54.5% (6/11) CyCMV/Flu-vaccinated survived. Survival correlates magnitude influenza-specific CD4 + prior challenge. These data demonstrate targeting proteins can highly pathogenic heterologous support further exploration cell-based for universal development.

Language: Английский

Citations

2
Effect of metabolic status on response to SIV infection and antiretroviral therapy in nonhuman primates DOI Creative Commons
Gabriela M. Webb, Kristin A. Sauter, Diana Takahashi

et al.

JCI Insight, Journal Year: 2024, Volume and Issue: 9(18)

Published: Aug. 8, 2024

Current antiretroviral therapy (ART) regimens efficiently limit HIV replication, thereby improving life expectancy of people living with HIV, but also cause metabolic side effects. The ongoing obesity epidemic has resulted in more comorbidities at the time infection, yet impact pre-existing dysregulation on infection sequelae and response to ART is unclear. Here, investigate preexisting insulin resistance acute subsequent long-term ART, we infected a cohort lean obese adult male macaques SIV administered ART. responses were similar respect plasma cell-associated viral loads, drug levels tissues, SIV-specific immune responses, adipose tissue islet morphology, colon inflammation, baseline differences between groups largely maintained. Both exhibited striking depletion CD4+ T cells from that did not recover However, differential observed for body weight, omental adipocyte size, adiponectin/leptin ratio, marker cardiometabolic risk. Thus, had limited effects multiple while several factors underlie influenced by prior resistance. These studies provide foundation future investigations into efficacy adjunct therapies such as metformin glucagon-like peptide-1 receptor agonists prevention HIV.

Language: Английский

Citations

2
CD8+ cells and small viral reservoirs facilitate post-ART control of SIV replication in M3+ Mauritian cynomolgus macaques initiated on ART two weeks post-infection DOI Creative Commons
Olivia E. Harwood, Lea M. Matschke, Ryan V. Moriarty

et al.

PLoS Pathogens, Journal Year: 2023, Volume and Issue: 19(9), P. e1011676 - e1011676

Published: Sept. 25, 2023

Sustainable HIV remission after antiretroviral therapy (ART) withdrawal, or post-treatment control (PTC), remains a top priority for treatment. We observed surprising PTC in an MHC-haplomatched cohort of MHC-M3+ SIVmac239+ Mauritian cynomolgus macaques (MCMs) initiated on ART at two weeks post-infection (wpi). None the MCMs possessed MHC haplotypes previously associated with SIV control. For six months we undetectable transient viremia seven eight MCMs, despite detecting replication competent using quantitative viral outgrowth assays. In vivo depletion CD8α+ cells induced rebound all animals, indicating was mediated, least part, by cells. With intact proviral DNA assays, found that had significantly smaller reservoirs wpi than identically infected rhesus macaques, population rarely develops PTC. similarly small reservoir among additional SIV+ which wpi, some whom exhibited rebound. These results suggest unusually is hallmark MCMs. By evaluating immunological differences between did and not rebound, identified reduced frequency CD4+ CD8+ lymphocyte subsets expressing exhaustion markers. Together, these combination immune-mediated virus suppression contribute to Further, defining immunologic mechanisms engender this model may identify therapeutic targets inducing durable humans.

Language: Английский

Citations

5
Stem cell transplantation and allogeneic immunity: post treatment control or HIV cure? DOI

Megan Cleary,

Lishomwa C. Ndhlovu, Jonah B. Sacha

et al.

Current Opinion in HIV and AIDS, Journal Year: 2024, Volume and Issue: 20(1), P. 86 - 91

Published: Nov. 1, 2024

Long-lasting HIV remission has been reported in a small group of people with (PWH) following allogenic hematopoietic stem cell transplants (HSCT) for the treatment hematologic malignancies. While mechanisms release from antiretroviral therapy (ART) were not initially known, subsequent findings clinical cases and preclinical nonhuman primate studies have implicated clearance. Here, we review six currently published human long-term ART-free remission.

Language: Английский

Citations

1